Statement by Coherus CEO Regarding Biosimilars Use
Post# of 301275
REDWOOD CITY, Calif., March 02, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS ), today announced that Coherus BioSciences’ Vice President of Government Affairs, Juliana Reed testified in support of the reauthorization of the Biosimilar User Fee Program for FY2018 –FY2022 (BsUFA II) on behalf of the Biosimilars Forum at the House Energy and Commerce Committee hearing on FDA’s generic drug and biosimilar user fee programs.
Ms. Reed spoke in support of the reauthorization of BsUFA II, highlighting its importance to not only the biosimilars industry, but also to patients and the healthcare system as a whole.
Denny Lanfear, President and Chief Executive Officer of Coherus BioSciences, stated: “I would like to communicate our unequivocal support of BsUFA II and emphasize how important adequate funding and support of the FDA biosimilars program is to the success of our industry and the future increased patient access and cost-savings these medicines will bring. On behalf of Coherus BioSciences, I strongly encourage Congress to demonstrate its support of the FDA and biosimilars by reauthorizing BsUFA II in a timely manner.”
You can read Ms. Reed’s full testimony by following the link below:
https://energycommerce.house.gov/hearings-and...e-programs
About Coherus BioSciences, Inc. Coherus is a leading pure-play, global biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production, sales & marketing and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-0214 (etanercept biosimilar) and CHS-1420 (adalimumab biosimilar), as well as developing a robust pipeline of future products in four therapeutic areas, oncology, immunology (anti-TNF), ophthalmology and multiple sclerosis. For additional information, please visit www.coherus.com .
CONTACT: Patrick O'Brien Senior Vice President, Investor Relations Coherus BioSciences, Inc. pobrien@coherus.com +1 (650) 649-3527
(0)
(0)